Bristol-Myers Squibb Analyst Price Targets

Wall Street analyst price targets and consensus rating for Bristol-Myers Squibb (BMY).

Price Target Range — 13 Quarters

Analyst Consensus — 23 Analysts

9Buy

13Hold

1Sell

Consensus RatingNeutral# Analysts23Avg. Consensus PT$61Upside to Avg. PT-2.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 30, 2026	Morgan Stanley	Terence Flynn	PT Cut	Underweight	$41→$40
Oct 26, 2026	Piper Sandler	David Amsellem	PT Cut	Overweight	$82→$78
Oct 13, 2026	Wells Fargo	Mohit Bansal	PT Cut	Equal-Weight	$65→$60
Oct 8, 2026	Cantor Fitzgerald	Carter Gould	PT Cut	Neutral	$59→$53
Oct 7, 2026	Morgan Stanley	Terence Flynn	PT Raise	Underweight	$40→$41
Oct 5, 2026	Leerink Partners	David Risinger	Downgrade	Outperform→Market Perform	$73→$59
Sep 16, 2026	Piper Sandler	David Amsellem	PT Raise	Overweight	$75→$82
Sep 10, 2026	HSBC	Rajesh Kumar	PT Raise	Hold	$60→$65
Aug 5, 2026	Argus Research	Jasper Hellweg	Upgrade	Hold→Buy	$75
Aug 3, 2026	Citigroup	Geoff Meacham	PT Raise	Neutral	$66→$70
Jul 31, 2026	RBC Capital	Trung Huynh	PT Raise	Sector Perform	$60→$64
Jul 31, 2026	JP Morgan	Chris Schott	PT Raise	Overweight	$67→$73
Jul 31, 2026	Cantor Fitzgerald	Carter Gould	PT Raise	Neutral	$54→$59
Jul 31, 2026	Wells Fargo	Mohit Bansal	PT Raise	Equal-Weight	$60→$65
Jul 31, 2026	Guggenheim	Seamus Fernandez	PT Raise	Buy	$72→$75
Jul 31, 2026	Truist Securities	Robyn Karnauskas	Maintained	Buy	$65→$70
Jul 10, 2026	B of A Securities	Tim Anderson	PT Cut	Buy	$67→$66
Jul 6, 2026	Cantor Fitzgerald	Carter Gould	Maintained	Neutral	$54
Apr 9, 2026	B of A Securities	Tim Anderson	PT Cut	Buy	$68→$67
Apr 8, 2026	Guggenheim	Seamus Fernandez	Maintained	Buy	$72

Analyst Ratings News

PRO
Morgan Stanley Maintains Underweight on Bristol-Myers Squibb, Lowers Price Target to $40

Morgan Stanley analyst Terence Flynn maintains Bristol-Myers Squibb (NYSE:BMY) with a Underweight and lowers the price target from $41 to $40.

Benzinga Newsdesk

PRO
Piper Sandler Maintains Overweight on Bristol-Myers Squibb, Lowers Price Target to $78

Piper Sandler analyst David Amsellem maintains Bristol-Myers Squibb (NYSE:BMY) with a Overweight and lowers the price target from $82 to $78.

Benzinga Newsdesk

PRO
Wells Fargo Maintains Equal-Weight on Bristol-Myers Squibb, Lowers Price Target to $60

Wells Fargo analyst Mohit Bansal maintains Bristol-Myers Squibb (NYSE:BMY) with a Equal-Weight and lowers the price target from $65 to $60.

Benzinga Newsdesk

Why Is Contineum Therapeutics Stock Falling Monday?

BMS trial results trigger a 29% drop in Contineum (CTNM), but analysts highlight long-term potential for PIPE-791 in IPF.

Vandana Singh

PRO
Cantor Fitzgerald Maintains Neutral on Bristol-Myers Squibb, Lowers Price Target to $53

Cantor Fitzgerald analyst Carter Gould maintains Bristol-Myers Squibb (NYSE:BMY) with a Neutral and lowers the price target from $59 to $53.

Benzinga Newsdesk

PRO
Morgan Stanley Maintains Underweight on Bristol-Myers Squibb, Raises Price Target to $41

Morgan Stanley analyst Terence Flynn maintains Bristol-Myers Squibb (NYSE:BMY) with a Underweight and raises the price target from $40 to $41.

Benzinga Newsdesk

Bristol-Myers Squibb Co

ニュース

パートナーシップ

ベンジンガ・グローバル

Bristol-Myers Squibb Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Morgan Stanley Maintains Underweight on Bristol-Myers Squibb, Lowers Price Target to $40

PRO
Piper Sandler Maintains Overweight on Bristol-Myers Squibb, Lowers Price Target to $78

PRO
Wells Fargo Maintains Equal-Weight on Bristol-Myers Squibb, Lowers Price Target to $60

Why Is Contineum Therapeutics Stock Falling Monday?

PRO
Cantor Fitzgerald Maintains Neutral on Bristol-Myers Squibb, Lowers Price Target to $53

PRO
Morgan Stanley Maintains Underweight on Bristol-Myers Squibb, Raises Price Target to $41

People Also Watch

People Also Watch

Bristol-Myers Squibb Co

ニュース

パートナーシップ

ベンジンガ・グローバル

Bristol-Myers Squibb Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROMorgan Stanley Maintains Underweight on Bristol-Myers Squibb, Lowers Price Target to $40

PROPiper Sandler Maintains Overweight on Bristol-Myers Squibb, Lowers Price Target to $78

PROWells Fargo Maintains Equal-Weight on Bristol-Myers Squibb, Lowers Price Target to $60

Why Is Contineum Therapeutics Stock Falling Monday?

PROCantor Fitzgerald Maintains Neutral on Bristol-Myers Squibb, Lowers Price Target to $53

PROMorgan Stanley Maintains Underweight on Bristol-Myers Squibb, Raises Price Target to $41

People Also Watch

People Also Watch

PRO
Morgan Stanley Maintains Underweight on Bristol-Myers Squibb, Lowers Price Target to $40

PRO
Piper Sandler Maintains Overweight on Bristol-Myers Squibb, Lowers Price Target to $78

PRO
Wells Fargo Maintains Equal-Weight on Bristol-Myers Squibb, Lowers Price Target to $60

PRO
Cantor Fitzgerald Maintains Neutral on Bristol-Myers Squibb, Lowers Price Target to $53

PRO
Morgan Stanley Maintains Underweight on Bristol-Myers Squibb, Raises Price Target to $41